MIDLOTHIAN, Va., Sept. 29, 2021 /PRNewswire/ -- Pulmotect reported positive topline results from their randomized, placebo-controlled Phase-2 trial of PUL-042 against COVID-19. Patients treated with ...
MIDLOTHIAN, Va., May 7, 2020 /PRNewswire/ -- This week, the first patients are enrolling in two phase 2 clinical trials for COVID-19 using Pulmotect's PUL-042, an inhaled immunomodulatory agent to ...
Sellbyville, DE -- (SBWIRE) -- 06/18/2019-- Pneumatic Nebulizers Market size is set to exceed USD 875 million by 2024; according to a new research report by Global Market Insights. Rising elderly ...
The US Food and Drug Administration (FDA) has approved the eRapid nebulizer system (PARI), the first electronic nebulizer to deliver dornase alfa (Pulmozyme, Genentech) for the treatment of cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback